Adenoviral delivery of CTLA4lg into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients

Keyphrases

• Allogeneic 100%
• Dendritic Cells 100%
• Adenoviral Delivery 100%
• Myeloid Dendritic Cells 100%
• Tolerogenicity 100%
• CD86 25%
• T Cells 12%
• Immune Response 12%
• Cell Toxicity 12%
• MHC Class II 12%
• CD28 12%
• Genetic Engineering 12%
• Lymphoid Tissue 12%
• Marker Genes 12%
• Functional Properties 12%
• Antigen-presenting Cells 12%
• Peripheral Tolerance 12%
• Naïve T Cells 12%
• T Cell Activation 12%
• Alloantigen 12%
• Central Tolerance 12%
• T Cell Proliferation 12%
• Immunoglobulin 12%
• Adenoviral Vector 12%
• Enhanced Green Fluorescent Protein (eGFP) 12%
• Cytotoxic T Cell Response 12%
• Hyporesponsiveness 12%
• Supernatant 12%
• Lymphocyte Activation 12%
• CD80 12%
• LacZ 12%
• Local Injection 12%
• Mixed Leukocyte Reaction 12%
• Allostimulatory Activity 12%
• Specific T Cells 12%
• Costimulatory Molecules 12%
• Cytotoxic T-lymphocyte antigen-4 (CTLA-4) 12%
• Cell Surface Staining 12%

Immunology and Microbiology

• Dendritic Cell 100%
• Myeloid Dendritic Cell 100%
• Immune Tolerance 25%
• CD86 25%
• T Cell 25%
• Lymphoid Tissue 12%
• T Cell Proliferation 12%
• Cytotoxic T Cell 12%
• T Cell Activation 12%
• Antigen-Presenting Cell 12%
• Immune Response 12%
• Intravenous Immunoglobulin 12%
• CD28 12%
• MHC Class II 12%
• Naive T Cell 12%
• Alloantigen 12%
• Cell Surface 12%
• CD80 12%
• Marker Gene 12%
• Mixed Lymphocyte Reaction 12%
• Adenovirus Vector 12%
• CTLA-4 12%
• Lymphocyte Activation 12%